Andy Scharenberg, Umoja Biopharma CEO
Umoja to dose first patient with in vivo CAR-T by end of this year
Umoja Biopharma has the FDA’s green light to dose the first patient with what it believes could be a more readily accessible CAR-T therapy. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
